On this page Agenda Applications for consideration at this meeting 1353 Measurement of Calprotectin as a marker of bowel inflammation 1372.1 MRI for patients with colorectal carcinoma (CRC) with suspected hepatic metastases or patients with suspected hepatocellular carcinoma (HCC) for the purposes of staging 1376.1 70 gene signature (MammaPrint) for use in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit 1434 Anti-Müllerian hormone testing 1435 Processing and Cryopreservation of Male and Female Gonadal Tissue and Gametes Prior to or after Gonadotoxic Treatment to Preserve Fertility for the Future 1440.1 PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer 1449 Genetic testing for Alport syndrome 1460 Blue-light cystoscopy with hexaminolevulinate as an adjunct to standard white light cystoscopy, for the diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC) 1467 Obstetric MRI 1475 Ablative fractional laser resurfacing for burn scar treatment Related information Committee: Medical Services Advisory Committee (MSAC)